What is DCOY's market cap?

$746.91K, based on the Nov 4 close of $1.14.

Does Decoy Therapeutics pay a dividend?

No regular cash dividend has been paid in the last year.

How much of DCOY is sold short?

97.6K shares, 16.8% of float, as of Oct 15, 2026.

What sector is DCOY in?

Healthcare, in the Pharmaceuticals industry.

NASDAQ · DCOYHealthcarePharmaceuticals

Decoy Therapeutics Inc. Common Stock (DCOY)

$1.14+2.70%

Close Nov 4, 2026 · split-adjusted

Nov 2, 2026$1.03▼ 88.80% in range

Jan 8, 2026Low $0.92 · High $90.98Nov 2, 2026

What changed · written from our data

As of Nov 4, 2026

Decoy Therapeutics closed at $1.14 on Nov 4, up 2.70%, 98.7% below its highest close since Jan 8. Volume of 16.7K shares was 0.24× its 20-day average (below normal).

Split-adjusted performance: -26.5% over one month, -81.0% over six months.

In the quarter ended Jun 30, 2026, revenue was $227.63K, with a net margin of -1042.8%.

Short interest was 97.6K shares at the Oct 15 settlement, down 35.1% from the prior report (16.8% of float, 1.0 days to cover).

Market cap$746.9K655.2K shares

Revenue · quarter$227.6K—

Diluted EPS$-4.46—

P/E · TTM—

Net margin-1,042.8%Gross 100.0%

Dividend yieldNone

Range since Jan 80.92 – 90.98−98.7% from high

Volume16.7K0.24× 20-day avg

Volatility · 60d123.4%Annualised

Short % of float16.8%1.0 days to cover

Net cash$8.3MCash $8.3M

Next earnings—Not scheduled

Split-adjusted performance

1W +3.6%1M −26.5%3M −71.9%6M −81.0%YTD —1Y —3Y —5Y —

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum7

Revenue growth—

Net margin22

Value (low P/E)—

Size1

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →

Shares short97.6K−35.1% vs prior

Days to cover1.0Settled Oct 15

% of float16.8%

Short vol. 10d31.9%of daily volume

Closest peers by size in Pharmaceuticals

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
DCOYDecoy Therapeutics	$1.14	+2.70%	−81.0%	—	−1042.8%	—	$746.9K
NXTSNexentis Technologies	$0.5550	−2.46%	—	—	—	—	$806.6K	Compare
VBIOValion Bio	$0.5171	−2.60%	—	—	—	—	$1.1M	Compare
JAGXJaguar Health	$0.4988	−10.53%	−97.6%	−58.9%	−1036.8%	—	$1.2M	Compare
MTNBMatinas BioPharma Holdings	$1.19	+4.39%	−88.3%	—	—	—	$1.2M	Compare
LABTLakewood-Amedex Biotherapeutics	$0.1914	−1.85%	—	—	—	—	$453.6K	Compare
ARTLArtelo Biosciences	$2.27	−5.42%	−90.9%	—	—	—	$1.2M	Compare
GOVXGeoVax Labs, Inc. New	$0.1680	+2.38%	−89.8%	−100.0%	—	—	$1.5M	Compare
ELABPMGC Holdings	$1.92	−1.03%	−91.0%	—	−225.1%	—	$1.6M	Compare

News about Decoy Therapeutics

All news →

No recent articles focused on Decoy Therapeutics.

Quick answers

What does Decoy Therapeutics do?: Decoy Therapeutics Inc is a pre-clinical stage biotechnology company focused on advancing its pipeline of peptide conjugate therapeutics engineered through its proprietary IMP3ACT platform. The IMP3ACT platform represents a paradigm shift in peptide conjugate drug discovery and manufacturing, leveraging machine learning (ML) and artificial intelligence (AI" tools alongside high-speed synthesis techniques to rapidly engineer, optimize and manufacture peptide conjugates that target serious unmet medical needs.
What is DCOY's market cap?: $746.91K, based on the Nov 4 close of $1.14.
Does Decoy Therapeutics pay a dividend?: No regular cash dividend has been paid in the last year.
How much of DCOY is sold short?: 97.6K shares, 16.8% of float, as of Oct 15, 2026.
What sector is DCOY in?: Healthcare, in the Pharmaceuticals industry.

About Decoy Therapeutics

Decoy Therapeutics Inc is a pre-clinical stage biotechnology company focused on advancing its pipeline of peptide conjugate therapeutics engineered through its proprietary IMP3ACT platform. The IMP3ACT platform represents a paradigm shift in peptide conjugate drug discovery and manufacturing, leveraging machine learning (ML) and artificial intelligence (AI" tools alongside high-speed synthesis techniques to rapidly engineer, optimize and manufacture peptide conjugates that target serious unmet medical needs. The company manages its business in one operating segment, focused on the discovery and development therapeutics for patients with high, unmet medical needs. Its pipeline programs include: Pan-Coronavirus; and Tripledemic.

HQ: Houston, TX11 employeesListed Jan 29, 2015decoytx.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology